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Background: Nodding syndrome is an epidemic symptomatic generalized epilepsy syndrome of unknown cause in
Eastern Africa. Some patients have extreme short stature. We hypothesized that growth failure in nodding
syndrome is associated with specific endocrine dysfunctions. In this pilot study, we examined the relationship
between serum hormone levels and stature, bone age and sexual development.
Results: We recruited ten consecutive children, 13 years or older, with World Health Organization defined nodding
syndrome and assessed physical growth, bone age, development of secondary sexual characteristics and serum
hormone levels. Two children with incomplete results were excluded. Of the eight remaining, two had severe
stunting (height for age Z [HAZ] score < -3) and three had moderate stunting (HAZ score between-3 and -2). The
bone age was delayed by a median 3(range 0-4) years. Serum growth hormone levels were normal in all eight but
the two patients with severe stunting and one with moderate stunting had low levels of Somatomedin C (Insulin
like Growth Factor [IGF1]) and/or IGF binding protein 3 (IGFBP3), mediators of growth hormone function. A linear
relationship was observed between serum IGF1 level and HAZ score. With the exception of one child, all were either
pre-pubertal or in early puberty (Tanner stages 1 and 2) and in the seven, levels of the gonadotrophins (luteinising
and follicle stimulating hormone) and the sex hormones (testosterone/oestrogen) were all within pre-pubertal
ranges or ranges of early puberty. Thyroid function, prolactin, adrenal, and parathyroid hormone levels were all
normal.
Conclusions: Patients with nodding syndrome may have dysfunctions in the pituitary growth hormone and
pituitary gonadal axes that manifest as stunted growth, delayed bone age and puberty. Studies are required to
determine if such endocrine dysfunction is a primary manifestation of the disease or a secondary consequence
of chronic ill health and malnutrition and if so, whether targeted interventions can improve outcome.
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Nodding syndrome is an emerging and debilitating
epidemic neurologic disorder that affects children and
adolescents in parts of Eastern Africa [1-6]. There are an
estimated 5000 - 10,000 affected children in the region
[7]. This probably symptomatic generalized epilepsy syn-
drome is characterized by head nodding determined to
be atonic seizures [5], and complicated by the develop-
ment of other seizure types, cognitive and motor decline,* Correspondence: ridro1@gmail.com
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article, unless otherwise stated.malnutrition, behavior and psychiatric difficulties [4].
The etiology remains unknown, however there has been
an association with infestation by Onchocerca volvulus,
the parasitic cause of river blindness [2,3,8,9]. Current
treatments are symptomatic and include seizure control
with antiepileptic drugs, nutritional and physical therapy
and rehabilitation and, management of psychiatric diffi-
culties [7].
Several patients with nodding syndrome have extreme
short stature and delayed development of secondary sex-
ual characteristics [4]. The pathogenesis of this growth
failure and delay in the onset of puberty are unknown.
Similar short stature has been reported in Nakalanga
syndrome: a syndrome with many physical characteris-
tics similar to nodding syndrome. In particular, patientsntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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secondary sexual characteristics, and very low height for
age z-scores compared to control children [10-12]. We
hypothesized that nodding syndrome is associated with
specific endocrine dysfunctions and that such dysfunc-
tion may manifest with growth failure, delayed bone
growth and puberty. In this pilot study, we assessed
consecutive patients with nodding syndrome, measured
serum hormone levels and examined the relationship




This was a pilot cross sectional survey of hormone levels
in Ugandan adolescents with nodding syndrome.
Participants
Participants were consecutive patients aged 13 years and
older with confirmed nodding syndrome as defined by
the World Health Organization criteria [13] and attend-
ing follow up care in Kitgum General Hospital. All had a
diagnostic EEG for seizure classification. Eight of the ten
patients were part of the 22 who had had detailed clin-
ical, neurophysiologic and brain imaging reported [4].
Procedures
The study was approved by Makerere University School
of Medicine Research and Ethics Committee. Parental
consent was obtained but no assent was requested
because of cognitive difficulties in the subjects.
Assessment of physical maturity and puberty
Details of the clinical assessment was reported earlier
[4]. Sexual maturity was assessed using the Tanner Sexual
Maturity Staging. Anthropometric measures were obtained;
standing height was determined using a stadiometer and
weight using an electronic weighing scale. The height for
age, weight for height and weight for age Z scores were cal-
culated using CDC 2000 standards. In addition, x-rays of
the left wrist were performed to determine bone age and
reported using a Greulich and Pyle Atlas [14]. Bone growth
was considered delayed if it was 2 years lower than the
chronological age.
Laboratory measurements
We drew 10 milliliters of early morning fasting blood to
assess endocrine function. The endocrine tests were per-
formed by a blinded technician (unaware of the patient
group) in an independent laboratory. The tests included
vitamin D, thyroid function (TSH, T3 and T4), growth
hormone, IGF 1 and IGFBP3, epiandrosterone and corti-
sol, testosterone, prolactin, estradiol, follicle stimulating
hormone and luteinising hormone. No stimulation testswere performed in this preliminary study. Assays for
TSH, T3, T4, cortisol, DHEA, FSH, LH, estradiol, testoster-
one, vitamin D and parathyroid hormone were performed
using the Cobas e411 analyser (Roche Diagnostics), a fully
automated immunoassay. Levels of IGF1 and IGFBP3 were
determined using an Enzyme linked immunosorbant assay
(ELISA) Diagnostic system Laboratories Inc. (DSL). A level
of IGF1 of 220 – 972 ng/ml and IGFBP3 of 3.3-10 μg/ml
was considered normal; vitamin D levels of 30-100 ng/ml
was sufficient, moderate deficiency was defined as 10-
29 ng/ml and severe deficiency as <10 ng/ml.
Data analysis
Children were categorised into three height for age
(HAZ) z scores of < -3, -3 to -2 and > -2. The primary
outcome measure was the proportion of patients with
abnormal hormone levels in the different endocrine
pathways in children with the three different HAZ score
groups.
Results
Demographic features and general clinical characteristics
Ten patients were assessed. Two were excluded; the first
had incomplete results and the second was later found
to be younger than 13 years old. The median age of the
remaining eight was 15 (range 13–18) years. Five were
female and three, male. The median age at onset of the
signs of nodding syndrome as observed by the family
was 7 (range 5–9) years, the median duration of the
signs at the time of the study was 8 (range 5–9) years
and in all cases, the onset of signs was between the years
2002 – 2008.
Three patients were classified as having head nodding
only while five had head nodding plus (head nodding
and other seizure types) [2]. Prior to presentation, all
had been on varying doses of Carbamazepine. Other
previous anticonvulsants included Phenytoin and Pheno-
barbitone. There was no clear benefit with any of these
treatments; thus, all were continuing to experience fre-
quent head nodding and/or other seizures. In addition,
all had moderate to severe cognitive impairment. Five
had behavior and psychiatric difficulties including wan-
dering, aggression, anxiety, and depression. One child
had psychotic behavior. Table 1 summarizes the patient
characteristics.
Physical growth, sexual maturity and endocrine function
Two of the eight patients had severe stunting (HAZ
score < -3), three had moderate stunting (HAZ score -3
to -2) and the remaining three had normal height (HAZ
score > -2). Compared to the chronologic age (median
14 [range 13-18] years), the bone age (median 11 [range
9-17] years) was delayed by a median 3 (range 0-4) years.
Children with stunting had the most disparity in bone
























1 15, Male 8 Head nodding only; Frequent head nods, triggered by
food; has difficulties in speech
- 4.75 −4.04 2 10 21.3 157 2.8
2 14, Female 9 Head nodding only; head nods triggered by food or
appearing spontaneously. Three siblings and cousins
also have NS.
−1.85 −1.49 2 12 23.0 286 4.3
3 13, Male 8 Head nodding plus; Head nods appear spontaneously;
Frequent hallucinations
−1.53 −2.63 1 9 21.9 295 4.1
4 15, Female 9 Head nodding plus; head nods triggered by food and
cold weather. Aggressive behaviour and often disoriented.
−5.05 −3.07 2 Not done 33.7 216 3.8
5 18, Female 8 Head nodding plus; head nods triggered by food;
periods of being aggressive; visual hallucinations
−1.11 −0.10 3 17 25.2 231 3.4
6 14, Female 5 Head nodding only; head nods triggered by food;
3 other siblings also have nodding syndrome.
−1.42 −1.78 2 12 25.8 332 4.6
7 13, Female 6 Head nodding plus; head nods are spontaneous;
Severe burn injury with a submental fistula
−3.17 −2.62 2 10 19.3 268 3.9
8 13, Female 6 Head nodding plus; Head nods triggered by food and
occur spontaneously. Severe and uncontrolled seizures,
behavior difficulties and psychotic behavior
−3.22 −2.23 1 10 18.8 164 3.8
9** 15, Male 2 Head nodding only −3.25 −3.05 1 Not done 34.6 No result No result
HAZ score < -3 = severe stunting, HAZ score -3 to -2 =moderate stunting and HAZ > -2 = Normal. Vitamin D deficiency level < 30 ng/ml; Normal IGF1 = 220-972 ng/ml,
IGFBP3 = 3.3-10 ug/ml Tanner staging was based on breast development for girls and testicular size for boys. **Excluded patient because of incomplete results.
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tients with median 22.5 (range 18.8-33.7) ng/ml and all
eight had osteopenia on x ray. The parathyroid hormone
levels were however appropriate, Table 2.
Growth hormone levels were normal (<5.4 ug/ml) in
all eight patients, median 0.52 (range 0.12-1.06) ug/ml.
The median Insulin like growth factor (IGF1) level was
250 (range 157- 332) ng/ml and the median IGF binding
protein 3 (IGFBP3) level was 3.7 (range 2.8-4.6) μg/ml.
Three patients (two with severe stunting and one of theTable 2 Median (ranges) plasma levels of hormone in
children with nodding syndrome
Test (units) Normal range Median (range in
patients
FT4 (pmol/l) 8.8 – 13.5 10.5 (8.8 – 20.1)
TSH (μIU/ml) 0.7 – 3.4 2.3 (1.27 – 3.18)
Cortisol (nmol/l) 171 - 536 256 (180 – 379)
DHEA (μmol/l 0.84 – 8.16 1.9 (0.84 – 5.24)
Parathyroid Hormone (pg/ml) 15 - 65 23.5 (16 - 65)
Prolactin (μg/l) 3.34 -26.71 5.75 (3.12 – 20)
FSH (IU/l) ** 4.4 (2.0 – 7.5)
LH (IU/l) ** 2.7 (1.5 – 7.9)
Estradiol (pmol/l) ** 169 (66 - 585)
Testosterone (nmol/l) ** 6.6 (5.2 -15.8)
**Normal limits of FSH, LH, testosterone and estradiol depend on sex and stage
of sexual development.three with moderate stunting) had low IGF1 levels. One
of the two children with severe stunting also had low
IGFBP3 level. IGF1 levels were however similar regard-
less of whether the child had head nodding only or head
nodding plus (other seizures). Serum albumin levels
were also normal in all the patients and there was no re-
lationship between severe wasting and IGF1 or IGFBP3
levels. A linear relationship was however observed be-
tween serum IGF1 and the HAZ score, Figure 1.
Other than one child in Tanner Sexual Maturity Stage
3, all the other children were either pre-pubertal or in
early stages of puberty. The profile of the gonadotrophins
(luteinising and follicle stimulating hormone) and the
sex hormones of testosterone/estrogen in these children
further revealed values within the pre-pubertal or early
stages of puberty. However, all eight patients had normal
thyroid function with normal levels of thyroid stimulating
hormone, T4 and T3. Adrenocorticotropic hormone and
the adrenal corticosteroid and mineralocorticoid hormone
levels were also all normal.Growth, age at onset of disease and hormone levels
Only one child had onset of symptoms before the age of
five years. We therefore did not assess the effect of early
onset of symptoms on growth or endocrine function. In
addition, all remaining seven patients had similar dur-

















Height for age Z scores
Figure 1 Serum S-Somatomedin levels and Height for age Z scores in eight adolescents with nodding syndrome. There is a linear
relationship between the HAZ score and serum S-Somatomedin level.
Piloya-Were et al. BMC Research Notes 2014, 7:858 Page 4 of 5
http://www.biomedcentral.com/1756-0500/7/858Discussion
Nodding syndrome has been associated with growth fail-
ure. Like many other questions surrounding the syn-
drome, the mechanisms underlying the growth failure
and delay in sexual development are unknown. This
study explored if specific endocrine abnormalities in
these patients was associated with the delayed growth
and sexual development. The study found abnormal hor-
mone levels in the pituitary-growth hormone axis, and
in particular, low levels of IGF1 and IGFBP3 in patients
with stunted growth, and delayed onset of puberty was
associated with abnormal hormone levels in pituitary-
gonadal axis and with low serum levels of the gonado-
tropins and sex hormones. In addition, almost all had
low serum vitamin D levels. On the other hand, thyroid
and adrenal hormone levels were normal.
Implications of the findings
This is a pilot study based on only a handful of patients.
Despite this limitation, the study suggests that endocrine
dysfunctions in the growth hormone axis and the go-
nadal axis may be an important factor in the growth
failure observed in adolescents with nodding syndrome.
A more important question though is whether such
dysfunction is a primary manifestation of the disease (for
example, one that is mediated by an on-going inflamma-
tory process) or is a secondary consequence of severe
disease, chronic ill health and malnutrition. Psycho-
logical trauma from the longstanding rebel insurgency
and the long period of suffering the community has ex-
perienced [15] may also have contributed to the suppres-
sion of the pituitary growth hormone and the gonadal
axes. It is however unclear why the other axes including
thyroid, parathyroid and adrenal hormones have remained
normal. Understanding which of these pathways is respon-
sible is likely to be important in targeting treatments. Ifendocrine dysfunction is secondary to severe disease, pro-
viding symptom control should result in correction of
dysfunction and stimulation of growth. Furthermore, the
mechanisms by which endocrine dysfunction develops
could also be helpful in understanding the pathogenesis of
nodding syndrome and bring us closer to determining
etiology of the disease. Thus, a more detailed, larger and
longer-term study is urgently required to examine which
pathways is likely and may include growth hormone and
gonadotropin stimulation tests.
Secondly, with a median 3 years of delayed bone age,
there is room for catch up growth on current stature if,
perhaps growth can be stimulated with symptomatic
therapeutic interventions such as anticonvulsants and
nutrition support or with more specific therapies such as
treatment with growth hormone. However, with the long
period of chronic ill health and malnutrition patients
have experienced or disease processes possibly causing
injury in the hypothalamic-pituitary areas, the most
stunted patients are unlikely to achieve their target adult
height despite the interventions.
The wide spread Vitamin D deficiency could be due to
nutritional (dietary) deficiency, a side effect of prolonged
use of the older anticonvulsants, the chronic debilitating
disease or secondary to limited exposure to sunlight as
patients remain hidden in houses due stigma. It is sug-
gested that supplemental Vitamin D in patients with
pharmaco-resistant epilepsy improves seizure control
[16]. Therapeutic correction of Vitamin D deficiency
should therefore be considered in nodding syndrome.
Conclusions
Patients with nodding syndrome may have dysfunctions in
the pituitary growth hormone and pituitary gonadal axes.
These dysfunctions possibly manifest with stunted growth,
delayed bone age and puberty. Studies are required to
Piloya-Were et al. BMC Research Notes 2014, 7:858 Page 5 of 5
http://www.biomedcentral.com/1756-0500/7/858determine if this is a primary manifestation of the disease
or a secondary consequence of chronic ill health and
malnutrition and if so, whether targeted interventions can
improve outcome.
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